Sterne Agee Resumes Coverage on Allscripts Healthcare Solutions with Buy Rating, $17 PT on Continued Long-Term Turnaround

In a report published Wednesday, Sterne Agee analyst Greg T. Bolan resumed coverage on Allscripts Healthcare Solutions MDRX with a Buy rating and $17.00 price target. In the report, Sterne Agee noted, “We believe Allscripts is in the 3rd inning of a long-term turnaround. The company has reshuffled executive leadership, rightsized-(ing) its organization, launched major product upgrades, and scuttled legacy ambulatory products. With a void only filled by two major players within the integrated acute-ambulatory clinical marketplace, we think Allscripts is retooling its organization to be a formidable third player. Re-initiating with Buy rating and $17 price target.” Allscripts Healthcare Solutions closed on Tuesday at $13.75.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorInitiationAnalyst RatingsGreg T. BolanSterne Agee
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!